SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following its CES announcements, highlighted by the new Vera Rubin AI platform entering full production with significantly enhanced performance, alongside the CFO's affirmation of growing demand beyond initial forecasts and a robust supply chain. Despite this overwhelmingly bullish news and strategic partnerships in physical AI and autonomous driving, community discussion reveals widespread frustration over the stock's constrained price action, which many attribute to heavy options activity. The focus remains on NVIDIA's foundational role in the expanding AI infrastructure, even as some question its near-term upside given recent sideways trading.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is trending due to recent upward price momentum, significantly bolstered by news of C2 Blockchain expanding its substantial $DOG treasury, signaling increasing institutional adoption for this Bitcoin-native asset. The dedicated "DOG Army" vigorously promotes $DOG as the decentralized "king of meme coins," emphasizing its secure foundation directly on Bitcoin's layer one and its potential to lead the sector by embodying Bitcoin's core ethos.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing a significant surge, driven by strong market narratives around the AI supercycle and increased demand for memory and storage, including reported shortages of SSDs and DDR5 RAM. Community sentiment is polarized, with many celebrating its role in AI infrastructure and expecting further gains, while others caution of a speculative bubble and actively explore shorting opportunities. This rapid appreciation has sparked intense debate regarding the sustainability of its current valuation within the broader memory sector.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is drawing significant attention as its comparative advantages in lower transaction fees and faster speeds are highlighted amidst Bitcoin network activity. The community is actively discussing an impending supply squeeze and key technical resistance levels, alongside optimism around its interoperability developments and increasing institutional interest in the broader digital asset space.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble (RUM) is trending as the community anticipates the imminent completion of its Northern Data acquisition, which is set to significantly boost its AI cloud infrastructure. Discussions are actively centered on high short interest, fueling speculation of a potential short squeeze, alongside excitement for the upcoming Rumble Wallet and expanding strategic partnerships with Tether.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending as community discussion intensifies around a potential showcase of its advanced batteries in smart eyewear at CES 2026 through a collaboration with Jorjin Group. This comes alongside reports of a major electrolyte supply deal, which many interpret as a strong indicator of imminent production scale, despite lingering skepticism over past timeline shifts and ongoing validation testing of AI-1 battery samples by a lead smartphone OEM.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as geopolitical tensions, notably around Venezuela and escalating global conflicts, are driving widespread speculation about a significant market volatility spike. Despite its historical decay challenges, traders are actively debating if current events will finally ignite a sustained upward move for this 2x leveraged VIX futures ETF, or if it remains primarily a short-term trading instrument.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver ($AGQ) is trending as the community intensely debates silver's future, driven by reports of impending export restrictions from a major global supplier and ongoing industrial demand. This has ignited strong bullish sentiment predicting a significant price discovery phase, while others caution about speculative overheating and market manipulation, fueling extreme volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing substantial bullish momentum, fueled by high-profile acknowledgments of severe memory bottlenecks and the accelerating AI supercycle. The company's strategic focus on high-growth data center segments, alongside robust demand and rising DRAM prices, has the community buzzing about its significant re-rating potential and perceived undervaluation.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is trending following positive preliminary revenue results that exceeded expectations, alongside multiple analyst upgrades to its price target. The community is actively discussing the company's critical role as a semiconductor substrate supplier for high-growth sectors like AI, 5G, and photonics, with many anticipating a significant upward move and potential short squeeze. This renewed interest is further bolstered by recent resolutions regarding export permits for its indium phosphide products from China.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due...

Arrowhead Pharmaceuticals Shares Early RNAi Obesity Data, Highlights Visceral Fat Drops and Combo Potential

Arrowhead Pharmaceuticals (NASDAQ:ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity candidates, ARO-INHBE and ARO-ALK7, during a virtual key opinion leader (KOL...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week High - Time to Buy?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year High - Here's What Happened...

Arrowhead Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) saw some unusual options trading on Tuesday. Traders purchased 5,093 call options on the company. This represents an increase of...

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.read more...

<ul class="summary-bullets"><li>The interim data show that ARO-INHBE, especially when combined with tirzepatide, doubled weight loss and tripled reductions in visceral fat.</li><li>In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.</li><li>ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans.</li></ul>Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 15% in Tuesday’s premarket, after it released early data from its Phase 1/2a clinical trials of its RNA interference (RNAi) therapies, ARO-INHBE and ARO-ALK7, targeting obesity.&nbsp;The preliminary results suggest these investigational treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.<h2 class="st-heading-2">Promising Fat Reduction</h2>The interim data show that ARO-INHBE, especially when combined with tirzepatide, a GLP-1/GIP receptor co-agonist, doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared with tirzepatide alone.The findings mark the first human evidence that targeting the Activin E/ALK7 pathway could enhance weight loss beyond that achieved by existing incretin therapies. In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.On Stocktwits, retail sentiment around Arrowhead stock jumped to ‘bullish’ from ‘bearish’ territory. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_081204_png_73fc92d26b.webp" alt="ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Clinical Highlights</h2>ARO-INHBE monotherapy at week 16 led to a 9.9% reduction in visceral fat, a 38% drop in liver fat, and a 3.6% increase in lean muscle. Two doses at week 24 further improved visceral fat reduction to 15.6% after adjusting for placebo.&nbsp;Combined with tirzepatide, ARO-INHBE achieved roughly double the weight loss and triple the fat reduction compared to tirzepatide alone.ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans, reducing ALK7 mRNA in fat tissue by an average of 88% at the 200 mg dose, with a peak reduction of 94%. Early data also showed a 14.1% reduction in visceral fat after a single dose at week 8, adjusted for placebo.ARWR stock has gained over 227% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-stock-draws-bullish-retail-chatter-ahead-of-key-investor-event-trader-calls-it-potential-multibagger/cmxwMoyR4T0">Ondas Stock Draws Bullish Retail Chatter Ahead Of Key Investor Event – Trader Calls It ‘Potential Multibagger’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

Why Did ARWR Stock Surge Over 15% Pre-Market Today? 

The preliminary results from Phase 1/2a clinical trials of the company’s  RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.

Equity

The preliminary results from Phase 1/2a clinical trials of the company’s  RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.


Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the companys investigational RNA interference (RNAi...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 13,187 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 13,187 shares of the firm's stock in a transaction dated Friday, January 2nd. The shares were...

Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 40,164 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James Hamilton sold 40,164 shares of the firm's stock in a transaction dated Monday, January 5th. The stock was sold at an...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) COO Sells $3,123,503.23 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) COO Patrick O'brien sold 49,493 shares of the firm's stock in a transaction on Monday, January 5th. The stock was sold at an average...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$70.81
Prev Close	$63.88
Open	$72.07
Dividend Yield	0.00%
50-Day Moving Average	$54.27
Beta	1.57
Avg. Volume	2.67M
PE Ratio	-1,053.72

52-Week High	$76.76
52-Week Low	$9.57
Market Capitalization	$8.68B
EPS (Annual)	-$0.0122
Price to Book	20.62
Revenue Per Employee	$1.17M
Enterprise Value/EBITDA	N/A

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARWR News

ARWRArrowhead Pharmaceuticals Inc.